Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Mass spectrometry-based proteomics has become an indispensable tool for system-wide protein quantification in systems biology, biomedical research, and increasing for clinical applications. In particular, targeted mass spectrometry offers the most sensitive and reproducible quantitative detection of proteins, peptides and post-translational modifications of any currently applied mass spectrometry technique and is therefore ideally suited to generate high quality quantitative datasets. Despite these apparent advantages, targeted mass spectrometry is only slowly gaining popularity in academia and pharmaceutical industries, mainly due to the additional efforts in assay generation and manual data validation. However, with the increasing accumulation of mass spectrometry data, advances in deep learning spectral prediction for automated assay development, these obstacles can and will be considerably reduced in the near future. Here, we describe the latest technological developments in this field and discuss the emerging importance of targeted mass spectrometry for systems biology research and potential key roles in bridging biomedical discovery and clinical implementation.

Original publication

DOI

10.2533/chimia.2022.81

Type

Journal article

Journal

Chimia (Aarau)

Publication Date

23/02/2022

Volume

76

Pages

81 - 89

Keywords

DIA, Parallel reaction monitoring, Selected reaction monitoring, SureQuant, TOMAHAQ, Targeted mass spectrometry